Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

This Phase 1B study showed that a single tablet of 300 mg of posaconazole, given once daily as prophylaxis to 210 patients at risk for invasive fungal disease, was as safe as that reported for posaconazole oral suspension and achieved steady-state >500 ng/mL for all but one patient.

authors

Cornely, Oliver A
Duarte, Rafael F
Haider, Shariq
Chandrasekar, Pranatharthi
Helfgott, David
Jiménez, Javier López
Candoni, Anna
Raad, Issam
Laverdiere, Michel
Langston, Amelia
Kartsonis, Nicholas
Van Iersel, Marlou
Connelly, Nancy
Waskin, Hetty

status

published

publication date

March 1, 2016

has subject area

0605 Microbiology (FoR)
1108 Medical Microbiology (FoR)
1115 Pharmacology and Pharmaceutical Sciences (FoR)
Administration, Oral (MeSH)
Adolescent (MeSH)
Adult (MeSH)
Aged (MeSH)
Aged, 80 and over (MeSH)
Antifungal Agents (MeSH)
Chemoprevention (MeSH)
Female (MeSH)
Fungemia (MeSH)
Hematologic Neoplasms (MeSH)
Humans (MeSH)
Immunocompromised Host (MeSH)
Male (MeSH)
Microbiology (Science Metrix)
Middle Aged (MeSH)
Plasma (MeSH)
Survival Analysis (MeSH)
Tablets (MeSH)
Triazoles (MeSH)
Young Adult (MeSH)

published in

Journal of Antimicrobial Chemotherapy Journal